Drugging the PI3 kinome: from chemical tools to drugs in the clinic.

The phosphatidylinositide 3-kinase (PI3K) pathway is very commonly activated in a wide range of human cancers and is a major driving force in oncogenesis. One of the class I lipid kinase members of the PI3K family, p110alpha, is probably the most commonly mutated kinase in the human genome. Alongside genetic, molecular biological, and biochemical studies, chemical inhibitors have been extremely helpful tools in understanding the role of PI3K enzymes in signal transduction and downstream physiological and pathological processes, and also in validating PI3Ks as therapeutic targets. Although they have been valuable in the past, the early and still frequently employed inhibitors, wortmannin and LY294002, have significant limitations as chemical tools. Here, we discuss the case history of the discovery and properties of an increasingly used chemical probe, the pan-class I PI3K and mammalian target of rapamycin (mTOR) inhibitor PI-103 (a pyridofuropyrimidine), and its very recent evolution into the thienopyrimidine drug GDC-0941, which exhibits excellent oral anticancer activity in preclinical models and is now undergoing phase I clinical trials in cancer patients. We also illustrate the impact of structural biology on the design of PI3K inhibitors and on the interpretation of their effects. The challenges and outlook for drugging the PI3 kinome are discussed in the more general context of the role of structural biology and chemical biology in innovative drug discovery.

[1]  Holger Gerhardt,et al.  Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration , 2008, Nature.

[2]  P. Workman.  Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeutics. , 2005, Cold Spring Harbor symposia on quantitative biology.

[3]  M. Waterfield,et al.  Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors. , 2006, Bioorganic & medicinal chemistry.

[4]  R. Hoffman,et al.  The effect of CXCL12 processing on CD34+ cell migration in myeloproliferative neoplasms. , 2010, Cancer research.

[5]  K. Kinzler,et al.  Dissecting isoform selectivity of PI3K inhibitors: the role of non-conserved residues in the catalytic pocket. , 2008, The Biochemical journal.

[6]  M. Kloor,et al.  Somatic hypermethylation of MSH2 is a frequent event in Lynch Syndrome colorectal cancers. , 2010, Cancer research.

[7]  Ralph Weissleder,et al.  Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers , 2008, Nature Medicine.

[8]  Ian Collins,et al.  New approaches to molecular cancer therapeutics , 2006, Nature chemical biology.

[9]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[10]  P. Cohen,et al.  Specificity and mechanism of action of some commonly used protein kinase inhibitors. , 2000, The Biochemical journal.

[11]  C. Croce,et al.  Oncogenic role of miR-483-3p at the IGF2/483 locus. , 2010, Cancer research.

[12]  Paul Workman,et al.  Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. , 2008, Current opinion in pharmacology.

[13]  Tudor I. Oprea,et al.  A crowdsourcing evaluation of the NIH chemical probes. , 2009, Nature chemical biology.

[14]  P. Workman.  Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. , 2003, Molecular cancer therapeutics.

[15]  Paul Workman,et al.  Pharmacodynamic biomarkers for molecular cancer therapeutics. , 2007, Advances in cancer research.

[16]  Massimo Libra,et al.  PIK3CA mutations in human solid tumors: Role in sensitivity to various therapeutic approaches , 2009, Cell cycle.

[17]  Paul Workman,et al.  Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma , 2009, Cell cycle.

[18]  Wei Zhou,et al.  In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models , 2009, Clinical Cancer Research.

[19]  Bert Vogelstein,et al.  The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. , 2007, Science.

[20]  K. Okkenhaug,et al.  Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation , 2006, Nature.

[21]  J. Chien,et al.  Downregulation of HtrA 1 Promotes Resistance to Anoikis and Peritoneal Dissemination of Ovarian Cancer Cells , 2010 .

[22]  P. Workman,et al.  Corrigendum: Drugging the PI3 kinome , 2006, Nature Biotechnology.

[23]  Robbie Loewith,et al.  A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling , 2006, Cell.

[24]  M. Zvelebil,et al.  Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction , 1996, Molecular and cellular biology.

[25]  Alice T. Loo,et al.  PTEN-deficient cancers depend on PIK3CB , 2008, Proceedings of the National Academy of Sciences.

[26]  P. Cohen,et al.  The selectivity of protein kinase inhibitors: a further update. , 2007, The Biochemical journal.

[27]  M. Sliwkowski,et al.  Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. , 2009, Cancer cell.

[28]  Anastassis Perrakis,et al.  Developments in the CCP4 molecular-graphics project. , 2004, Acta crystallographica. Section D, Biological crystallography.

[29]  R. V. van Montfort,et al.  Structure-based design of molecular cancer therapeutics. , 2009, Trends in biotechnology.

[30]  Chris T. Harvey,et al.  ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21. , 2010, Cancer research.

[31]  W. Lu,et al.  Tumor site-specific silencing of NF-κB p65 by targeted hollow gold nanosphere-mediated photothermal transfection (Cancer Research (2010) 70, (3177-3188) DOI: 10.1158/0008-5472.CAN-09-3379) , 2010 .

[32]  G. Mills,et al.  Therapeutic potential of phosphoinositide 3-kinase inhibitors , 2004 .

[33]  M. Baggiolini,et al.  Inhibition of the phagocytosis-induced respiratory burst by the fungal metabolite wortmannin and some analogues. , 1987, Experimental cell research.

[34]  P. Cohen.  Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.

[35]  S. Ward,et al.  The PI3K inhibitor arsenal: choose your weapon! , 2007, Trends in biochemical sciences.

[36]  William A Weiss,et al.  A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. , 2006, Cancer cell.

[37]  K. Shokat,et al.  Chemically targeting the PI3K family. , 2007, Biochemical Society transactions.

[38]  P. Workman,et al.  Drugging the PI3 kinome , 2006, Nature Biotechnology.

[39]  Pixu Liu,et al.  Targeting the phosphoinositide 3-kinase pathway in cancer , 2009, Nature Reviews Drug Discovery.

[40]  Yi Liu,et al.  The p110δ crystal structure uncovers mechanisms for selectivity and potency of novel PI3K inhibitors , 2009, Nature chemical biology.

[41]  M. Waterfield,et al.  Synthesis and biological evaluation of pyrido[3′,2′:4,5]furo[3,2- d ]pyrimidine derivatives as novel PI3 kinase p110α inhibitors , 2007 .

[42]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[43]  W. Yung,et al.  NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas , 2009, Molecular Cancer Therapeutics.

[44]  A. Arcaro,et al.  Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. , 1993, The Biochemical journal.

[45]  Nathan T. Ihle,et al.  Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy , 2009, Molecular Cancer Therapeutics.

[46]  M. Waterfield,et al.  Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2 -a]pyridines as novel PI3 kinase p110α inhibitors , 2007 .

[47]  Robert T Abraham,et al.  PI 3-kinase related kinases: 'big' players in stress-induced signaling pathways. , 2004, DNA repair.

[48]  P. Finan,et al.  Therapeutic potential of phosphoinositide 3-kinase inhibitors. , 2003, Chemistry & biology.

[49]  Christian Ried,et al.  Structural insights into phosphoinositide 3-kinase catalysis and signalling , 1999, Nature.

[50]  M. Waterfield,et al.  Synthesis and function of 3-phosphorylated inositol lipids. , 2001, Annual review of biochemistry.

[51]  Roger L. Williams,et al.  Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. , 2000, Molecular cell.

[52]  T. Schall,et al.  Tumor and Stem Cell Biology Cancer Research The Chemokine Receptor CXCR 7 Is Highly Expressed in Human Glioma Cells and Mediates Antiapoptotic Effects , 2010 .

[53]  R. V. van Montfort,et al.  PI(3) kinases: revealing the delta lady. , 2010, Nature chemical biology.

[54]  J. Ware,et al.  A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  M. Waterfield,et al.  Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110α inhibitors , 2007 .

[56]  Yiling Lu,et al.  AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. , 2009, Cancer cell.

[57]  W. Sellers,et al.  Drug discovery approaches targeting the PI3K/Akt pathway in cancer , 2008, Oncogene.

[58]  P. Workman,et al.  Application of meso scale technology for the measurement of phosphoproteins in human tumor xenografts. , 2007, Assay and drug development technologies.

[59]  K Y Hui,et al.  A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). , 1994, The Journal of biological chemistry.

[60]  M. Waterfield,et al.  Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. , 2007, Cancer research.

[61]  P. Foubert,et al.  Integrin α4β1 signaling is required for lymphangiogenesis and tumor metastasis (Cancer Research (2010) 70, (3042-51) DOI , 2010 .

[62]  M. Belvin,et al.  Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. , 2009, Cancer research.

[63]  Eli R. Zunder,et al.  Discovery of Drug-resistant and Drug-sensitizing Mutations in the Oncogenic Pi3k Isoform P110a , 2022 .

[64]  Bert Vogelstein,et al.  The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations , 2007, Science.

[65]  J. Heath,et al.  Signal transducers and activators of transcription-3 binding to the fibroblast growth factor receptor is activated by receptor amplification. , 2010, Cancer research.

[66]  T. Insel,et al.  NIH Molecular Libraries Initiative , 2004, Science.

[67]  J. Vincent,et al.  5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. , 2010, Cancer research.

[68]  Gary Box,et al.  The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer . , 2008, Journal of medicinal chemistry.

[69]  Bhramar Mukherjee,et al.  Gene Expression Patterns in Mismatch Repair-Deficient Colorectal Cancers Highlight the Potential Therapeutic Role of Inhibitors of the Phosphatidylinositol 3-Kinase-AKT-Mammalian Target of Rapamycin Pathway , 2009, Clinical Cancer Research.

[70]  J. F. Burrows,et al.  The deubiquitinating enzyme USP17 is highly expressed in tumor biopsies, is cell cycle regulated, and is required for G1-S progression. , 2010, Cancer research.

[71]  P. Workman,et al.  Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941 , 2009, Molecular Cancer Therapeutics.

[72]  A. Muotri,et al.  Coordination of centrosome homeostasis and DNA repair is intact in MCF-7 and disrupted in MDA-MB 231 breast cancer cells. , 2010, Cancer research.

[73]  P. Vogt,et al.  PI 3-kinase and cancer: changing accents. , 2009, Current opinion in genetics & development.

[74]  L. Cantley,et al.  PI3K pathway alterations in cancer: variations on a theme , 2008, Oncogene.

[75]  Perfecting probes. , 2009, Nature chemical biology.

[76]  D. Sutherlin,et al.  Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer. , 2010, Journal of medicinal chemistry.

[77]  P. Workman.  Drugging the cancer genome: new challenges of infrequent and combinatorial targets. , 2007, Current opinion in investigational drugs.

[78]  G. Demetri,et al.  A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  P. Fisher,et al.  Molecular mechanism of chemoresistance by astrocyte elevated gene-1. , 2010, Cancer research.

[80]  Lewis C Cantley,et al.  The phosphoinositide 3-kinase pathway. , 2002, Science.

[81]  P. Cohen,et al.  The specificities of protein kinase inhibitors: an update. , 2003, The Biochemical journal.

[82]  M. Belvin,et al.  Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab , 2009, Clinical Cancer Research.